Elysium Health
Corporate brand
UnclaimedElysium Health is a New York-based American dietary-supplement company focused on products and testing services associated with healthy aging, longevity, and age-related wellness.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Elysium Health is an American health and wellness company headquartered in New York City. Founded in 2014 by Leonard Guarente, Dan Alminana, and Eric Marcotulli, the company developed a consumer-facing business around nutritional supplements and biological-aging research. Its products are positioned at the intersection of longevity science, preventive health, and personalized measurement rather than conventional disease treatment. The company’s first major product was Basis, introduced in 2015. Basis combines nicotinamide riboside, a precursor associated with cellular NAD+ metabolism, with pterostilbene, a compound related to resveratrol. Elysium presented the formulation as a way to support cellular and metabolic processes associated with aging. The product helped establish the company’s identity as a science-oriented longevity brand, while also placing it in a commercially competitive and legally contested market for NAD-related ingredients and supplements. Elysium obtained $20 million in Series B financing in December 2016. Its business subsequently broadened beyond a single longevity supplement. In 2019, it introduced Index, a saliva-based epigenetic test intended to estimate biological age. The product reflected Elysium’s effort to connect supplementation with measurement and personal health data, although an epigenetic age estimate is not equivalent to a clinical diagnosis or a direct measure of remaining lifespan. The company expanded its product portfolio during the 2020s. Matter, launched in June 2020, was marketed around brain health and the preservation of cognitive function. Format, introduced in October 2021, was associated with healthy aging, immune support, and broader wellness claims. Mosaic followed in 2023 with a focus on skin aging and collagen protection. In October 2024, Elysium introduced Vision, a daily product positioned around macular health and eye longevity. Elysium’s public profile has also been shaped by disputes over the sourcing and patent position of nicotinamide riboside. ChromaDex, a supplier connected to Basis ingredients, and Dartmouth College brought patent litigation against Elysium in 2018. W. R. Grace and Company filed a separate patent case in 2020. The Dartmouth and ChromaDex claims were dismissed by a federal district court in 2021, and the United States Court of Appeals for the Federal Circuit affirmed the judgment in 2023, holding the asserted claims invalid under 35 U.S.C. § 101. These disputes are an important part of Elysium’s corporate history because they illustrate the intellectual-property competition surrounding longevity supplements. Elysium Health remains best understood as a direct-to-consumer, science-led supplement and testing brand. Its market proposition emphasizes research, proprietary formulations, and measurable aspects of aging, while its products remain dietary supplements or consumer tests rather than replacements for medical care. Publicly available reference material does not establish a parent company, exchange listing, ticker, or a complete current executive roster.
History
Elysium Health was established in 2014 by Leonard Guarente, Dan Alminana, and Eric Marcotulli in New York City. The founders built the company around translating research on aging biology into products sold directly to consumers. Rather than operating primarily as a pharmaceutical developer, Elysium adopted the dietary-supplement model and emphasized scientific formulation, research partnerships, and consumer education about longevity. The company’s first product, Basis, arrived in 2015. Its formulation contained nicotinamide riboside and pterostilbene, ingredients associated with cellular metabolism and antioxidant research. Basis gave Elysium a distinctive position in the emerging longevity market, but the ingredients also connected the company to disputes over supply agreements, commercial disclosures, and patent rights. ChromaDex had supplied ingredients used in Basis and later became a litigant in a broader conflict over nicotinamide riboside technology and patents. Elysium raised $20 million in Series B financing in December 2016. The funding supported the company’s expansion as it sought to develop a broader platform rather than rely on one supplement. In 2019, Elysium introduced Index, a test using epigenetic analysis of saliva samples to estimate biological age. Index extended the company’s proposition from taking supplements to monitoring a biological-age-related metric, although such estimates should not be confused with clinical diagnoses. The portfolio expanded further in the 2020s. Matter launched in June 2020 with claims and positioning related to brain health, cognitive maintenance, and slowing brain aging or atrophy. In October 2021, the company launched Format, associated with healthy aging and immune-system support. Mosaic, introduced in 2023, addressed skin aging and collagen protection. In October 2024, Vision broadened the range into eye wellness, with a focus on macular health and eye longevity. Litigation has been a significant part of the company’s history. In September 2018, Dartmouth College and ChromaDex sued Elysium for alleged infringement of patents involving nicotinamide riboside. The dispute followed earlier commercial dealings between Elysium and ChromaDex, including the supply of ingredients for Basis. In August 2020, W. R. Grace and Company filed another case concerning patents for crystalline nicotinamide riboside. In September 2021, a federal district court dismissed the Dartmouth and ChromaDex claims and effectively invalidated the patents at issue. In February 2023, the Federal Circuit affirmed the district court’s judgment, concluding that the asserted claims were invalid under section 101 of the U.S. patent statute. Elysium’s development reflects the wider commercialization of longevity science. Its products cover cellular aging, cognition, immune-related wellness, skin, and eye health, while Index provides a measurement-oriented service. The company’s public materials and product categories position it as a research-led consumer-health brand. Available reference material does not establish a public listing, ticker, parent company, or sufficiently documented current executive team.
- 2024
Vision introduced
[1]Elysium introduced Vision as a daily product for macular health and eye longevity.
- 2023
Mosaic launched
[1]Elysium introduced Mosaic for skin-aging and collagen-related support.
- 2021
Format launched
[1]Format joined the portfolio with positioning related to anti-aging and immune support.
- 2020
Matter launched
[1]Elysium introduced Matter as a brain-health and healthy-aging supplement.
- 2019
Index launched
[1]Elysium introduced Index, an epigenetic saliva test intended to estimate biological age.
- 2016
Series B financing
[1]The company received $20 million in Series B funding.
- 2015
Basis introduced
[1]Elysium launched Basis, its first product, containing nicotinamide riboside and pterostilbene.
- 2014
Company founded
[1]Leonard Guarente, Dan Alminana, and Eric Marcotulli founded Elysium Health in New York City.
Products and positioning
A science-oriented longevity and preventive-wellness brand combining dietary supplements with biological-age measurement and products aimed at cellular, cognitive, immune, skin, and eye health.
Longevity dietary supplement · 2015
Basis
Elysium’s first major supplement, launched in 2015. Basis contains nicotinamide riboside and pterostilbene and is positioned around cellular energy, NAD+ metabolism, and healthy aging. Its ingredients became central to later commercial and patent disputes involving Elysium and other companies.
Biological-age test · 2019
Index
A saliva-based test introduced in 2019 that uses epigenetic analysis to estimate biological age. Index represents Elysium’s effort to pair its supplement business with a consumer-facing measurement of an aging-related biological signal.
Brain-health supplement · 2020
Matter
Launched in June 2020, Matter is positioned around maintaining brain health and supporting cognitive longevity. Public descriptions associate it with efforts to slow or mitigate aspects of brain aging and atrophy.
Healthy-aging supplement · 2021
Format
Introduced in October 2021, Format is associated with anti-aging and immune-system support. It extends Elysium’s product range beyond the cellular-aging emphasis of Basis into broader daily wellness positioning.
Skin-health supplement · 2023
Mosaic
A daily supplement launched in 2023 and positioned around preventing or reducing visible skin aging and protecting collagen. It represents Elysium’s expansion into beauty-from-within and connective-tissue wellness.
Eye-health supplement · 2024
Vision
Introduced in October 2024, Vision is a daily product positioned to support macular health and promote eye longevity. It broadens the portfolio into age-related eye wellness.
Brand decisions
2023
Federal Circuit patent rulingOtherBackground
Patent litigation involving Dartmouth College, ChromaDex, and Elysium concerned claims related to nicotinamide riboside.
Action taken
The Federal Circuit affirmed the lower court’s judgment that the asserted claims were invalid under 35 U.S.C. § 101.
Aftermath
The ruling upheld Elysium’s success in that patent dispute.
2021
Launch of FormatProduct launchBackground
The company sought to offer a broader daily healthy-aging and immune-support product.
Action taken
Elysium introduced Format in October 2021.
Aftermath
Format expanded the brand’s consumer-health portfolio beyond Basis and Matter.
2020
Launch of MatterProduct launchBackground
Elysium broadened its portfolio into cognitive and brain-aging support.
Action taken
The company launched Matter as a supplement associated with brain health and healthy aging.
Aftermath
Matter added a neuro-wellness category to the company’s product range.
2019
Launch of IndexProduct launchBackground
Elysium expanded beyond supplementation into consumer measurement of aging-related biological signals.
Action taken
The company introduced an epigenetic saliva test intended to estimate biological age.
Aftermath
Index broadened Elysium’s longevity proposition toward testing and personalized health information.
2015
Launch of BasisProduct launchBackground
Elysium sought to establish a consumer longevity brand with a supplement centered on nicotinamide riboside and pterostilbene.
Action taken
The company introduced Basis as its first product.
Aftermath
Basis became the product at the center of later supplier and patent disputes involving nicotinamide riboside.
Recent events
Reported
Elysium Health and Oxford enter research collaboration[3]
Elysium Health entered into a material transfer agreement with the University of Oxford to analyze umbilical cord blood samples from the INTERBIO-21st Study for research into measures of early-childhood growth and neurodevelopment.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/elysium-health · Editorial policy · How profiles are compiled